Results from mangafodipir preclinical study are presented by IC Targets AS at the CMR Symposium in Oslo
Results from a preclinical animal study, using manganese-enhanced MRI (MEMRI) to assess the rate of manganese uptake in cardiomyocytes in vivo, are presented at the bi-annual Contrast Media Research (CMR) Symposium in Oslo, Norway.
The study evaluated a new, clinically improved MRI protocol and kinetic model for manganese-enhanced MRI (MEMRI) to assess the rate of manganese uptake in cardiomyocytes in vivo. The study results are presented by Jonny Østensen, IC Targets Project Leader, Cardiac.
Calcium cycling is an essential mediator of cardiac contractile function, and remodeling calcium handling is thought to be one of the major factors contributing to the dysfunction observed in heart failure.
Mangafodipir is an intracellular contrast agent in cardiac magnetic resonance imaging that provides information about the calcium channel activity of viable cardiac cells.
“Mangafodipir-enhanced MRI has potential as a noninvasive method to measure calcium channel activity and to detect T-tubule remodeling in heart failure, ischemic heart disease and cardiomyopathies. The procedure developed by IC Targets is relevant for the examination of patients with heart disease”, said Jonny Østensen.
Recently, IC Targets received approval in Norway to initiate its Phase 2A clinical trial with mangafodipir in patients with heart failure. “We are very excited to start enrollment of the first participants in our Proof-of-Concept (PoC) trial soon”, commented Christina Abrahamsberg, Chief Scientific Officer. “Our long-term goal is to get approval for mangafodipir-enhanced MRI (MEMRI) in all common heart diseases where calcium handling may be altered.”
This R&D project “Manganese-enhanced MRI in Heart Failure” has received funding from the Research Council of Norway within the category “Innovation Project for the Industrial Sector” under grant agreement # 327815.